Lists
Lists
Bakkar, Marwa Reda, Faraag, Ahmed Hassan Ibrahim, Soliman, Elham R. S., Fouda, Manar S., Sarguos, Amir Mahfouz Mokhtar, McLean, Gary R., Hebishy, Ali M. S., Elkhouly, Gehad E., Raya, Nermeen R. and Abo-zeid, Yasmin (2021) Rhamnolipids nano-micelles as a potential hand sanitizer. Antibiotics, 10 (7). pp. 1-21. ISSN 2079-6382
COVID-19 is a pandemic disease caused by the SARS-CoV-2, which continues to cause global health and economic problems since emerging in China in late 2019. Until now, there are no standard antiviral treatments. Thus, several strategies were adopted to minimize virus transmission, such as social distancing, face covering protection and hand hygiene. Rhamnolipids are glycolipids produced formally by Pseudomonas aeruginosa and as biosurfactants, they were shown to have broad antimicrobial activity. In this study, we investigated the antimicrobial activity of rhamnolipids against selected multidrug resistant bacteria and SARS-CoV-2. Rhamnolipids were produced by growing Pseudomonas aeruginosa strain LeS3 in a new medium formulated from chicken carcass soup. The isolated rhamnolipids were characterized for their molecular composition, formulated into nano-micelles, and the antibacterial activity of the nano-micelles was demonstrated in vitro against both Gram-negative and Gram-positive drug resistant bacteria. In silico studies docking rhamnolipids to structural and non-structural proteins of SARS-CoV-2 was also performed. We demonstrated the efficient and specific interaction of rhamnolipids with the active sites of these proteins. Additionally, the computational studies suggested that rhamnolipids have membrane permeability activity. Thus, the obtained results indicate that SARS-CoV-2 could be another target of rhamnolipids and could find utility in the fight against COVID-19, a future perspective to be considered.
Available under License Creative Commons Attribution 4.0.
Download (5MB) | Preview
 |
View Item |